1Zetia/label posted[EB/OL].http://www.fda.gov/cder/approval/index.htm April 29,2006 last visited.
2ALTMANN S W,DAVIS J H R,ZHU L J,et al.Niemann-pick C1like 1 protein is critical for intestinal cholesterol absorption[J].Science,2004,303:1201-1204.
3PATRICK J E,KOSOGLOU T,STAUBER K L,et al.Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects[J].Drug Metab Dispos,2002,30(4):430-437.
4KNOPP R H,DUJOVNE C A,LE BEAUT A,et al.Evaluation of the efficacy,safety,and tolerability of ezetimibe in primary hypercholesterolaemia:a pooled analysis from two controlled phase Ⅲclinical studies[J].Int J Clin Pract,2003,57 (5):363-368.
5GAGNE C,BAYS H E,WEISS S R,et al.Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia[J].Am J Cardiol,2002,90(10):1084-1091.
6GAGNE C,GAUDET D,BRUCKERT E.Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia[J].Circulation,2002,105 (21):2469-2475.
7SALEN G,VON BERGMANN K,LUTJOHANN D,et al.Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia[J].Circulation,2004,109(8):966-971.
8KOSOGLOU T,STATKEVICH P,FRUCHART J C,et al.Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe[J].Gurr Med Res Opin,2004,20(8):1197-1207.
9BILCHICK K C,HENRIKSON C A,SKOJEC D,et al.Treatment of hyperlipidemia in cardiac transplant recipients[J].Am Heart J,2004,148(2):200-210.
10WHO Collaborating Center for International Drug Monitoring.Ezetimibe labeling update regarding hypersensitivity reaction[J].WHO Pharm Neuslett,2003,(4):2.
6Casas JP, Shah T, Hingorani AD, et al. C-reactive protein and coro- nary heart disease:a critical review[ Jl. J Intern Med,2008,264: 295 -314.
7Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention [ J ]. Am Heart J, 2006,151 (2) :273-281.
8Gotto AM Jr. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin [ J ]. Am J Cardiol, 2005,96(5 ) :34-38.
9Cannon CP,Giuqliano RP,Blazing MA,et al. Rationale and design of IMPROVE-IT( IMProved Reduction of Outcomes : Vytorin Effica- cy International Trial ) : comparison of ezetimbe/simvastain versussimvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes [ J 1. Am Heart J, 2008,156 ( 5 ) : 826-832.
10Califf RM, Harrington RA, Blazing MA,et al. Premature release of data from clinical trials of ezetimibe[ J]. N Engl J Med,2009,361 (7) :712-717.
